Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance

Retention rate was lower after switching from OI to CT-P13 compared to our control cohorts. However, this difference faded after excluding patients without objective clinical activity, suggesting a reluctance of patients to the switch and a negative perception of the biosimilar.